Canaccord lowered the firm’s price target on iRhythm (IRTC) to $125 from $137 and keeps a Buy rating on the shares. The firm said they reported a solid Q3/24 and gave guidance in-line with expectations but they lowered their target to reflect both lower comp group multiples and slightly lower 2025 revenue due to the pushout of ZioMCT.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC: